Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous autovaccine versus placebo in adults with house dust mite allergy
2005-005534-12Phase 2Completed
- Sponsor
- Symbio Herborn Group
- Start
- Nov 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in house dust mite allergy, allergic rhinitis (AR), allergic conjunctivitis (AC) and 1 more comparing Autologous autovaccine with Placebo (2 arms). Primary endpoint: Reduction in exhaled nitric oxide. Started Nov 2005; status: completed.
02
Drugs
autologous autovaccine
03
Conditions
house dust mite allergyallergic rhinitis (AR)allergic conjunctivitis (AC)asthma
Beyond the preview
Go deeper on 2005-005534-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005534-12.